Idorsia Adds Hollywood Sparkle To Sleep Drug Quviviq
Jennifer Aniston To Front Unbranded Insomnia Ad Campaign
Executive Summary
The Swiss biotech needs to wait for a scheduling review before it can officially launch the insomnia drug Quviviq but this delay gives Idorsia a few months to prime the US market with educational campaigns.
You may also be interested in...
Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx
The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.
Merck KGaA Well-Equipped Against War And Raw Material Shortages
Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.